Seth A Wander

19PUBLICATIONS

148CO-AUTHORS

Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Economic models and forecastingHealth and ecological risk assessmentPredictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (19)

Sort by Publication Date:

|Jul 09, 2026

Beyond amplification: precision approaches to targeting HER2.

|Jul 07, 2026

SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast Cancer.

|Jul 02, 2026

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

|Nov 14, 2025

Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Hope S Rugo, Virginia Kaklamani, Heather McArthur

|Nov 07, 2025

Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Maxwell R Lloyd, Caroline M Weipert, Azka Ali

|Oct 27, 2025

Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancer.

Yael Bar, Steven J Isakoff, Seth A Wander

Pageof 4

Frequent Collaborators

Aditya Bardia

Steven J Isakoff

Leif W Ellisen

Dejan Juric

Laura Spring

Beverly Moy

Kevin Kalinsky

Maxwell R Lloyd

Amy Comander

Arielle Medford

Frequent Collaborators

Aditya Bardia

Steven J Isakoff

Leif W Ellisen

Dejan Juric